VREX - Varex Imaging Corporation
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Varex Imaging NASDAQ: VREX reported fiscal second-quarter revenue within its guidance range and said demand remained solid across its medical and industrial businesses, while management highlighted a completed debt refinancing and continued investment in advanced imaging technologies.
While the top- and bottom-line numbers for VAREX IMAGING (VREX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Varex Imaging Corporation (VREX) Q2 2026 Earnings Call Transcript
VAREX IMAGING (VREX) came out with quarterly earnings of $0.21 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.26 per share a year ago.
SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the second quarter fiscal year 2026. Q2FY26 Summary Revenues $216 million GAAP gross margin 34% | Non-GAAP gross margin* 34% GAAP operating margin 7% | Non-GAAP operating margin* 9% GAAP net loss $0.19 per diluted share | Non-GAAP net income* $0.21 per diluted share Cash outflows from operations of $2 million "Demand remained solid in the second quarter, with continued m.
The consensus price target hints at a 63.2% upside potential for VAREX IMAGING (VREX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2026, following the close of regular trading on Thursday, May 7, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this c.
VAREX IMAGING (VREX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in VAREX IMAGING (VREX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JPMorgan Chase and Co. grew its stake in shares of Varex Imaging (NASDAQ: VREX) by 381.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 284,227 shares of the company's stock after buying an additional 225,238 shares during the quarter. JPMorgan
High Tide (NASDAQ: HITI - Get Free Report) and Varex Imaging (NASDAQ: VREX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Insider and Institutional Ownership 4.5% of High
SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced it has entered into a Credit and Guaranty Agreement (the “Credit Agreement”), dated as of March 13, 2026, which includes a secured term loan facility in aggregate principal amount of $350 million, a secured revolving credit facility in aggregate principal amount of $100 million and a secured delayed draw term loan facility in aggregate principal amount of $40 million (collectively, the “Credit Facility”),.
SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the following upcoming investor conferences. Oppenheimer's 36th Annual Healthcare, MedTech & Services Virtual Conference: Tuesday, March 17, 2025 at 10:40am ET. Webcast link here. Sidoti Small Cap Virtual Conference: Wednesday, March 18, 2026 at 1:00pm ET. Webcast link here. The webcast can be accessed at the above links or on Varex's website at http://www.var.
SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) (the “Company” or “Varex”) today announced it has issued a notice of conditional full redemption of all of its outstanding 7.875% senior secured notes due October 15, 2027 (the “Notes”) on March 16, 2026 (the “Redemption Date”). The aggregate principal amount of the outstanding Notes is $368,000,000. The redemption price for the Notes will be equal to 101.969% of the principal amount of the Notes, together with accrued an.
Varex Imaging (NASDAQ: VREX - Get Free Report) was the target of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 1,243,917 shares, an increase of 53.1% from the January 29th total of 812,433 shares. Based on an average trading volume of 505,636 shares, the
Varex Imaging Corporation (VREX) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for VAREX IMAGING (VREX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
VAREX IMAGING (VREX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.07 per share a year ago.